3 ASX Stocks You’ve Never Heard of Set to Pop: Buy Alert

Most investors stick to the household names at the top end of the ASX, but some of the biggest moves on the market come from stocks flying completely under the radar. We've identified three lesser-known ASX names that look like they could be preparing to pop, and when these kinds of stocks move, the moves are often substantial.

In the latest episode of our Hot Stock Tips Show, Senior Analyst Filip Tortevski and Pedro Banales dig into the uncharted areas of the market to break down the catalysts, charts, and key levels behind each opportunity.

1. Aroa Biosurgery(ARX)

Aroa Biosurgery is a regenerative medicine company that develops products that help the body repair damaged tissue, heal wounds, and reconstruct soft tissue after surgery or injury. Its products are primarily used by surgeons, wound-care specialists, and hospitals.

The healthcare AI sector also continues to attract premium multiples from institutions. The most recent 13F filings out of the US, where major hedge funds disclose their quarterly holdings, revealed significant new buying in healthcare names, particularly healthcare AI stocks. The space is hot, but it's being accumulated quietly under the radar.

What the Chart is Telling Us

Looking at the monthly chart, Aroa has been in a downtrend since IPO. Right now, for the first time, something has changed. The stock has broken through long-term momentum, potentially signalling a major shift in price action. It has also established a serious level of support around 50 cents, which has been tested on multiple occasions, and it's now finding a base above both that support and the long-term downtrend.

The first major test will be at 80 cents. If Aroa can clear that level, the path opens up toward the dollar mark, which is often where institutional interest begins to build as stocks move into higher market cap weighting categories.

On the weekly chart, the retest of the recent low without breaking the previous all-time low at 35 cents is a very encouraging sign. If Aroa continues to make higher highs and higher lows, then breaks above 80 cents, the technical setup becomes very compelling. Healthcare is arguably the largest industry that AI is set to disrupt, and Aroa sits right at the intersection of both.

2. Wrkr Limited (WRK)

Wrkr Limited is a more illiquid play, but the catalyst behind it is what makes this stock genuinely interesting. From 1 July, changes to Payday Super will require employers to pay employee superannuation at the same time as wages, replacing the current quarterly payment system. This is one of the biggest payroll and superannuation rule changes in decades.

Wrkr Limited sits squarely in the middle of this regulatory shift. If management can execute well, the company has the potential to emerge as a key piece of Australia's superannuation payment infrastructure. They have recently onboarded major superannuation clients and acquired payroll compliance platform PaidRight. Revenue growth has been strong, although losses remain elevated, so this is very much a bet on future execution.

What the Chart is Telling Us

The price action shows a textbook pattern for a new stock with a serious catalyst. The IPO was dumped, followed by a period of strong accumulation, and the market is now in expansion mode. Buyers have driven the share price aggressively in anticipation of what could come, and the recent pullback is not surprising given how sharp the prior move was.

The key technical level is the seven cent zone. To remain in the expansionary phase, Wrkr needs to hold above this level. If it pulls back, it needs to bounce sharply and then break the previous high. Failure to do so opens the door back down toward three cents.

For higher-risk traders, current levels offer an early entry opportunity, but caution is warranted. If you're newer to the markets, this is exactly the kind of stock where having a structured framework for entries and risk management makes all the difference.

3. Acusensus (ACE)

Acusensus is a real business with real revenue and proven technology in road safety cameras and enforcement. Government contracts can create long-duration earnings streams, which is precisely the kind of recurring revenue profile that long-term investors look for.

What's particularly notable about this stock is how it has held up post-IPO. Most newly listed stocks turn the corner and head lower within six months of listing, with Guzman & Gomez being a recent example. Acusensus, however, listed in 2023 has been holding strong for three years now. That kind of post-IPO durability says something important about underlying demand.

What the Chart is Telling Us

Strong buying came in shortly after IPO in June 2023, and the stock has since produced the kind of price action you want to see from a quality growth name: higher highs and higher lows. It's currently pulling back, but importantly, it's reverting back to the sustainable rate of rise rather than breaking down.

The previous all-time high around $1.24 is now the key zone. The market has shot through it, and we're about to find out whether buyers are willing to defend that level on the way back down. If they are, that's a strong signal that the market believes this stock is worth more than where it traded previously. A turn in momentum somewhere above the $1.50 level would provide solid confirmation that the next leg is underway, with the next major target being a break above $1.70.

Volume is also picking up, which suggests genuine interest is building rather than just speculation. Combined with the support evident from previous all-time highs around 80 cents, the structure here is encouraging for patient investors.

The Common Thread: Why Education Beats Speculation

Each of these three stocks shares a common feature: a clear catalyst, a defined technical setup, and key levels that determine whether the trade works or not. What separates profitable traders from those who simply chase tips is the ability to read price action, identify these levels, and manage risk accordingly.

This is exactly what we focus on at Wealth Within. Our share trading education is built around teaching you how to identify these setups for yourself, so you're never reliant on someone else's tip to know when to act.

For those starting out, the Short Course in Share Trading provides a practical foundation in the techniques and strategies needed to trade safely and confidently. If you're ready to commit to a comprehensive, government-accredited program, the Diploma of Share Trading and Investment teaches a proven five-step approach, including the patterns and price analysis techniques referenced throughout this analysis. And for graduates wanting to refine their edge with techniques like time analysis and Elliott Wave, the Advanced stock trading course is the natural next step.

Final Thoughts

Aroa Biosurgery, Wrkr Limited, and Acusensus all sit well outside the mainstream coverage of most market commentary, yet each one has a genuine catalyst and a technical setup worth watching closely. Aora is showing the first real shift in price action since IPO, with healthcare AI continuing to attract serious institutional capital. Worker Limited is positioned at the heart of one of Australia's biggest superannuation reforms in decades. And Acusensus offers something rare in newly listed names: a multi-year track record of post-IPO strength backed by recurring government revenue.

As always, the difference between catching these moves and watching them go by comes down to skill, structure, and patience. Identify the levels, wait for confirmation, and manage your risk. With the right education and a disciplined approach, opportunities like these become far easier to act on with confidence.

Disclaimer: This article is general in nature and does not constitute personal financial advice. Always conduct your own research or consult a licensed adviser before making investment decisions.